Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cellectar Biosciences, Inc.
National Cancer Institute (NCI)
Novartis
Galapagos NV
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
BeOne Medicines
National Institutes of Health Clinical Center (CC)
AbbVie
Hoffmann-La Roche
Memorial Sloan Kettering Cancer Center
Genentech, Inc.
St. Jude Children's Research Hospital
National Institutes of Health Clinical Center (CC)
Eli Lilly and Company
Hoffmann-La Roche
Case Comprehensive Cancer Center
Taiho Oncology, Inc.
Thomas Jefferson University
Dartmouth-Hitchcock Medical Center
Celgene
Pfizer
Acerta Pharma BV
M.D. Anderson Cancer Center
Case Comprehensive Cancer Center
National Cancer Institute (NCI)
Werewolf Therapeutics, Inc.
Baylor College of Medicine
Washington University School of Medicine
Washington University School of Medicine
National Cancer Institute (NCI)
Eli Lilly and Company
City of Hope Medical Center
University of Michigan Rogel Cancer Center
Eli Lilly and Company
St. Jude Children's Research Hospital
Byondis B.V.
Case Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
UNC Lineberger Comprehensive Cancer Center
Hoffmann-La Roche
Novartis
Mayo Clinic
Fred Hutchinson Cancer Center
University of Chicago
Incyte Corporation